Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: A potential drug delivery route for tumor cells

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Kojic, Liliana D ^a   Wiseman, Sam M ^a   Ghaidi, Fariba ^a   Joshi, Bharat ^a   Nedev, Hinyu ^b   Saragovi, H Uri ^b   Nabi, Ivan R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOCRINE MOTILITY FACTOR; AUTOCRINE MOTILITY FACTOR GLUCOSE 6 PHOSPHATE ISOMERASE PACLITAXEL CONJUGATE; CAVEOLIN 1; FLUORESCEIN ISOTHIOCYANATE; GLUCOSE 6 PHOSPHATE ISOMERASE; PACLITAXEL; UNCLASSIFIED DRUG; AUTOCRINE MOTILITY FACTOR RECEPTOR; CYTOKINE RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN CACO 2; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MELANOMA B16; MOUSE; NONHUMAN; SOLID TUMOR; SPLEEN; THYMOCYTE; ANIMAL; CARCINOMA; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN HCT116; CHEMISTRY; COLON TUMOR; DRUG EFFECT; EVALUATION; MELANOMA; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOCRINE MOTILITY FACTOR; CACO-2 CELLS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GLUCOSE-6-PHOSPHATE ISOMERASE; HCT116 CELLS; HT29 CELLS; HUMANS; MELANOMA; MEMBRANE MICRODOMAINS; MICE; NEOPLASMS; PACLITAXEL; RECEPTORS, CYTOKINE; UBIQUITIN-PROTEIN LIGASES;

EID: 56349089024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003597     Document Type: Article

References (53)

1. Bareford LM, Swaan PW (2007) Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59: 748-758.
2. Marsh M, Helenius A (2006) Virus entry: open sesame. Cell 124: 729-740.
3. Kirkham M, Parton RG (2005) Clathrin-independent endocytosis: New insights into caveolae and non-caveolar lipid raft carriers. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1745: 273-286.
4. Lajoie P, Nabi IR (2007) Regulation of raft-dependent endocytosis. J Cell Mol Med 11: 644-653.
5. Predescu SA, Predescu DN, Malik AB (2007) Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am J Physiol Lung Cell Mol Physiol 293: L823-842.
6. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
7. Chiu CG, St-Pierre P, Nabi IR, Wiseman SM (2008) Autocrine motility factor receptor: a clinical review. Expert review of anticancer therapy 8: 207-217.
8. Benlimame N, Simard D, Nabi IR (1995) Autocrine motility factor receptor is a marker for a distinct tubular membrane organelle. J Cell Biol 129: 459-471.
9. Goetz JG, Genty H, St. Pierre P, Dang T, Joshi B, et al. (2007) Reversible interactions between smooth domains of the endoplasmic reticulum and mitochondria are regulated by physiological cytosolic calcium levels. J Cell Sci 120: 3553-3564.
10. Wang H-J, Guay G, Pogan L, Sauve R, Nabi IR (2000) Calcium regulates the association between mitochondria and a smooth subdomain of the endoplasmic reticulum. J Cell Biol 150: 1489-1498.
11. Goetz JG, Nabi IR (2006) Interaction of the smooth endoplasmic reticulum and mitochondria. Biochem Soc Trans 340: 370-373.
12. Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, et al. (2007) The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med 13: 1504-1509.
13. Gurney ME, Apatoff BR, Spear GT, Baumel MJ, Antel JP, et al. (1986) Neuroleukin: A lymphokine product of lectin-stimulated T cells. Science 234: 574-581.
14. Gurney ME, Apatoff BR, Heinrich SP (1986) Suppression of terminal axonal sprouting at the neuromuscular junction by monoclonal antibodies against a muscle-derived antigen of 56,000 daltons. J Cell Biol 102: 2264-2272.
15. Chaput M, Claes V, Portetelle D, Cludts I, Cravador A, et al. (1988) The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature (Lond) 332: 454-457.
16. Faik P, Walker JIH, Redmill AAM, Morgan MJ (1988) Mouse glucose-6-phosphate isomerase and neuroleukin have identical 3 sequences. Nature (Lond) 332: 455-457.
17. Xu W, Seiter K, Feldman E, Ahmed T, Chiao JW (1996) The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 87: 4502-4506.
18. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A (1996) Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 56: 2960-2963.
19. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, et al. (1986) Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83: 3302-3306.
20. Niinaka Y, Paku S, Haga A, Watanabe H, Raz A (1998) Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 58: 2667-2674.
21. Silletti S, Paku S, Raz A (1996) Tumor autocrine motility factor responses are mediated through cell contact and focal adhesion rearrangement in the absence of new tyrosine phosphorylation in metastatic cells. Am J Pathol 148: 1649-1660.
22. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A (2004) Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 10: 7775-7784.
23. Kanbe K, Chigara M, Watanabe H (1994) Effects of protein kinase inhibitors on the cell motility stimulated by autocrine motility factor. Biochim Biophys Acta 1222: 395-399.
24. Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A (2002) Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res 62: 4484-4490.
25. Yanagawa T, Watanabe H, Takeuchi T, Fujimoto S, Kurihara H, et al. (2004) Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta. Lab Invest 84: 513-522.
26. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H (2003) Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 107: 707-714.
27. Funasaka T, Haga A, Raz A, Nagase H (2001) Tumor Autocrine Motility Factor Is an Angiogenic Factor That Stimulates Endothelial Cell Motility. Biochem Biophys Res Comm 285: 118-128.
28. Funasaka T, Haga A, Raz A, Nagase H (2002) Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. Int J Cancer 101: 217-223.
29. Funasaka T, Yanagawa T, Hogan V, Raz A (2005) Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J 19: 1422-1430.
30. Tsutsumi S, Hogan V, Nabi IR, Raz A (2003) Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 63: 242-249.
31. Funasaka T, Hu H, Hogan V, Raz A (2007) Down-regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Expression Sensitizes Human Fibrosarcoma Cells to Oxidative Stress Leading to Cellular Senescence. J Biol Chem 282: 36362-36369.
32. Baumann M, Kappel A, Brand K, Siegfeld W, Paterok E (1990) The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 8: 351-356.
33. Bodansky O (1954) Serum phosphohexose isomerase in cancer II. As an index of tumor growth in metastatic carcinoma of the breast. Cancer 7: 1200-1226.
34. Filella X, Molina R, Jo J, Mas E, Ballesta AM (1991) Serum phosphohexose isomerase activities in patients with colorectal cancer. Tumor Biol 12: 360-367.
35. Guirguis R, Javadpour N, Sharareh S, Biswas C, el-Amin W, et al. (1990) A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers. J Occup Med 32: 846-853.
36. Patel PS, Rawal GN, Rawal RM, Patel GH, Balar DB, et al. (1995) Comparison between serum levels of carcinoembryonic antigen, sialic acid, and phosphohexose isomeras in lung cancer. Neoplasia 42: 271-274.
37. Schwartz MK (1973) Enzymes in cancer. Clin Chem 19: 10-22.
38. Benlimame N, Le PU, Nabi IR (1998) Localization of autocrine motility factor receptor to caveolae and clathrin-independent internalization of its ligand to smooth endoplasmic reticulum. Mol Biol Cell 9: 1773-1786.
39. Le PU, Guay G, Altschuler Y, Nabi IR (2002) Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J Biol Chem 277: 3371-3379.
40. Le PU, Nabi IR (2003) Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J Cell Sci 116: 1059-1071.
41. Kojic LD, Joshi B, Lajoie P, Le PU, Leung S, et al. (2007) Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol-3-kinase-dependent in breast carcinoma cells. J Biol Chem 282: 29305-29313.
42. Guillemard V, Saragovi HU (2001) Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res 61: 694-699.
43. Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435-10441.
44. Nabi IR, Raz A (1987) Cell shape modulation alters glycosylation of a metastatic melanoma cell surface antigen. Int J Cancer 40: 396-401.
45. Nabi IR, Raz A (1988) Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive variant. Cancer Res 48: 1258-1264.
46. Silletti S, Paku S, Raz A (1998) Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. Int J Cancer 76: 120-128.
47. Silletti S, Paku S, Raz A (1998) Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells. Int J Cancer 76: 129-135.
48. Leclerc N, Vallée A, Nabi IR (2000) Expression of the AMF/ neuroleukin receptor in developing and adult rat cerebellum. J Neurosci Res 60: 602-612.
49. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, et al. (2008) Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. In press.
50. Lajoie P, Nabi IR (2007) Regulation of raft-dependent endocytosis. J Cell Mol Med Submitted.
51. Guillemard V, Saragovi HU (2004) Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 4: 313-326.
52. Nabi IR, Watanabe H, Raz A (1990) Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res 50: 409-414.
53. Yang JL, Qu XJ, Russell PJ, Goldstein D (2005) Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. Oncology 69: 224-238.